|Day Low/High||154.68 / 158.32|
|52 Wk Low/High||113.36 / 160.56|
Why aren't we figuring out how to cure the test bottleneck?
Earnings reports continue to outperform, but can this support equity markets at these levels now?
Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
Some of the best opportunities are in lesser-known niche markets such as medical devices and services.
Also, defense industry names can breathe easier with word of debt ceiling and federal spending deal.
Here are some options strategies for this FANG name into tomorrow's report.
The crash of oil will only accelerate the move.
For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.
This will be the ninth consecutive year when the big game tops that 100 million-viewers mark.
It's a wonder to me how split this market really is.
These four stocks are showing short-term gain catalysts and longer-term growth potential.
Shares of Quest Diagnostics were slightly higher Tuesday after announcing an investigation into a data breach by a third-party that affected the health records of 34,000 people.
The 64 year old Tillerson became CEO of the Texas based oil giant in 2004 and has a close business relationship with Russian President Vladimir Putin.
Quest Diagnostics CEO Stephen Rusckowski discusses the Affordable Care Act and what's next for his company.
Here's a window into what institutional investors may be doing and how to profit from that.
LH's $5.7B Covance takeover could be just what the doctor ordered.
Quest could be vulnerable to a deep correction, but a decline to next support around $60 seems like the path of least resistance.